Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 44

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 44
---
 rote calculations under set formulas, is appropriate in responsibly discharging its duties. Our corporate accomplishments in 2024 were a direct product of the performance of our named executive officers, and thus, their individual contributions were an important factor in determining 2024 compensation. Following an assessment of our corporate accomplishments to the 2024 corporate goals, the compensation committee recommended, and our board approved, a corporate goal achievement percentage of 70% overall and an individual performance assessment of 100% for Dr. Koehler and Dr. Zinda. Mr. Segal’s bonus opportunity does not include an individual performance assessment component; rather, his target bonus is solely reflective of the corporate goal achievement percentage.

| Named Executive Officer    |     | 2024 Target (%  
 of Base Salary) |    |     | Actual 2024 
 Award ($)   |         |     | Actual 2024  
 Award (% of  
 Base Salary) |      |
| Lloyd M. Segal             |     |                 | 55 |     |             | 242,743 |     |              | 38.5 |
| Maria Koehler, M.D., Ph.D. |     |                 | 40 |     |             | 156,550 |     |              |   31 |
| Michael Zinda, Ph.D.       |     |                 | 40 |     |             | 147,095 |     |              |   31 |

Equity-Based Incentive Awards We grant equity-based incentive awards to our named executive officers from time to time, and these awards are designed to align the interests of our executive officers with those of our shareholders. 31

We have historically used stock options as an incentive for long-term compensation to our executive officers because they allow our executive officers to profit only if our share price increases above the exercise price established on the date of grant. All options are granted with an exercise price that is no less than the fair market value of our common shares on the date of grant of such award, determined based on the volume weighted average trading price of our common shares for the five trading days prior to the date of grant. Our stock option awards generally vest over a four-year period and may be subject to acceleration of vesting and exercisability under certain termination and change in control events. Our stock option awards have a ten-yearterm. We also use restricted stock unit awards (“RSUs”) as an incentive for long-term compensation to our executive officers. RSUs are less dilutive to our shareholders as fewer